Clinical Trial Update: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates ibrutinib in combination with rituximab for relapsed or refractory mantle cell lymphoma. The study has completed and its results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Mantle-Cell | Phase 2 | Status: COMPLETED | Results posted: 2025-01-13